Advertisement

Related Videos

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Advertisement

Advertisement




Aug
03
Today In Oncology
ACS Study Quantifies Financial Burden of Cancer in Older Patients
Transplant Consolidation Improves Survival in Primary CNS Lymphoma
Pirtobrutinib Triplet Improves Progression-Free Survival in Previously Treated CLL
NCI Names New CCR Director
Rectal Cancer AI Identifies Patients Most Likely to Benefit From Irinotecan-Intensified Neoadjuvant Chemoradiotherapy
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo